Yale researchers analyzed 396,333 DNA methylation sites and discovered that only 2.4% (9,363 CpGs) connect senescence, aging, and mortality risk. They developed three specialized epigenetic clocks targeting senescence, age, and mortality prediction. Remarkably, senolytic treatments—drugs designed to eliminate senescent cells—failed to reverse these DNA methylation signatures in both laboratory and living systems, with some clocks actually accelerating rather than slowing down. This unexpected finding fundamentally challenges two pillars of aging research. First, it questions whether DNA methylation patterns can reliably capture cellular senescence, despite epigenetic clocks being widely used as aging biomarkers in clinical trials. Second, it undermines the basic assumption that successful anti-aging interventions should measurably reduce aging biomarkers. The research suggests that senescent cell removal may not reset the molecular 'aging clock' as expected, potentially because senescence-driving methylation changes become permanently embedded in surviving cells. This paradigm-shifting work demands a reconsideration of how we measure anti-aging intervention success and whether epigenetic age reversal is a realistic therapeutic goal, even when interventions successfully target aging mechanisms.